Review of the History and Current Status of Cell-Transplant Approaches for the Management of Neuropathic Pain

Table 4

Stem/Precursor cell lines.

Source	Model	Results
Stem/Progenitors: Rat spinal (embryonic) progenitor cells [184]; Adrenal progenitors—human [281]	Partial nerve injury (CCI) [184]	(i) Reduced thermal hyperalgesia [184]
Human neuronal/progenitors: Human NT2 cell line [205, 282, 283]	Excitotoxic SCI pain [283]	(i) Release cannabinoids [282]; (ii) Antinociceptive [283]
Human NT2.17 GABA cell line [212, 225, 226, 228, 283, 284]	Excitotoxic SCI (QUIS) [212, 225, 226, 283–285]; Streptozotocin-induced diabetic peripheral neuropathy (DPN) [283]; Partial nerve injury (CCI) [228, 283]	(i) Antinociceptive [212, 226, 228, 283]; (ii) Restores spinal GABA DH inhibition [228]; (iii) Colocalize/release GABA and glycine [212]
Human NT2.19 5HT cell line [213, 241, 283]	(i) Contusive SCI [213, 241]; (ii) Excitotoxic SCI [283]	(i) Intraspinal grafts attenuate motor dysfunction [213]; (ii) Intrathecal grafts provide antinociception [241, 283]